Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Gemini Space Station Inc (GEMI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Gemini Space Station Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while Gemini Space Station Inc trades at $4.2 (market cap $528.49M). The key difference: ACADIA Pharmaceuticals Inc. is far larger — about 8.5× Gemini Space Station Inc's market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Gemini Space Station Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | GEMI | |
|---|---|---|
Market Cap | $4.49B | $528.49M |
Sector | Health | Technology |
52-Week High | $28.06 | $32.52 |
52-Week Low | $20.06 | $3.91 |
Enterprise Value | $3.69B | $518.47M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Gemini Space Station (GEMI) trades at $4.41, up 4.26% today, but remains in a bearish technical trend with significant fundamental challenges. The company reported a net loss of $582.81 million in 2025, with negative gross and net income margins, and has missed earnings expectations for three consecutive quarters. Recent news includes a $100 million investment from Winklevoss Capital but also multiple class-action lawsuits alleging securities law violations.
The outlook is highly speculative. Analyst consensus suggests modest upside to a $5.95 price target, but persistent losses, legal overhangs, and negative cash flow from operations pose substantial risks. Investment appeal hinges on the company's ability to monetize its super app strategy and achieve profitability, which remains uncertain.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Gemini Space Station Inc
Gemini Space Station Inc is the parent company of the Gemini crypto ecosystem, founded by Cameron and Tyler Winklevoss. It operates as a regulated digital asset exchange and custodian, providing a platform for individuals and institutions to trade, store, and stake cryptocurrencies while serving as a trusted bridge between legacy finance and the decentralized web.
Read more on GEMI →
